The research results indicate that the incidence of arteriovenous thrombotic events in ITP patients receiving TPO-RAs treatment is 2–3 times higher than that in patients not receiving TPO-RAs treatment (Tjepkema et al., 2022), and platelet count is not linearly correlated with thrombotic events (van Dijk et al., 2021). Here, TPO is linked to autoimmune thrombocytopenic purpura.